Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 5
Submit an article Journal homepage
2,660
Views
3
CrossRef citations to date
0
Altmetric
HPV – Research Paper

The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age

Chao Zhaoa Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, ChinaView further author information
,
Yun Zhaoa Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, ChinaView further author information
,
Jingran Lia Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, ChinaView further author information
,
Mingzhu Lia Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, ChinaView further author information
,
Yanyan Sub Department of Obstetrics and Gynecology, Shunyi Maternity and Child Health Hospital, Beijing, ChinaView further author information
,
Xin Mib Department of Obstetrics and Gynecology, Shunyi Maternity and Child Health Hospital, Beijing, ChinaView further author information
,
Su Yi La Tuc Department of Obstetrics and Gynecology, Xilinguolemeng Xianghuangqi Maternity and Child Health Hospital, Inner Mongolia Autonomous Region, ChinaView further author information
,
Danhua Shena Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, ChinaView further author information
,
Lihua Rena Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, ChinaView further author information
,
Yanyan Lia Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, ChinaView further author information
,
Linhong Wangd National Center for Women and Children’s Health, Chinese Center for Disease Control and Prevention, Beijing, ChinaView further author information
&
Lihui Weia Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1388-6691View further author information
ORCID Icon show all
Article: 2052700 | Received 14 Dec 2021, Accepted 10 Mar 2022, Published online: 31 Mar 2022

References

  • de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018. Lancet Glob Health. 2020;8(2):e180–6. doi:10.1016/S2214-109X(19)30488-7.
  • de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. doi:10.1002/ijc.30716.
  • Food and Drug Administration. Summary basis for regulatory action - Gardasil 9. 2018 [accessed 2021 Sep 1]. https://www.fda.gov/media/117054/download.
  • European Medicines Agency. Gardasil 9 - Human papillomavirus 9-valent vaccine (recombinant, adsorbed) (EMA/192711/2016). 2016 [accessed 2021 Sep 1]. https://www.ema.europa.eu/en/documents/overview/gardasil-9-epar-summary-public_en.pdf.
  • Chinese vaccine for HPV approved. 2020 [accessed 2021 Sep 1]. https://www.chinadaily.com.cn/a/202001/02/WS5e0d4067a310cf3e35581efd.html.
  • Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt R, Joura E. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–14. doi:10.1086/597071.
  • Wei LH, Xie X, Liu JH, Zhao Y, Chen W, Zhao C, Wang S, Liao X, Shou Q, Qiu Y, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up in Chinese women. Vaccine. 2019;37(27):3617–24. doi:10.1016/j.vaccine.2018.08.009.
  • Chen W, Zhao Y, Xie X, Liu J, Li J, Zhao C, Wang S, Liao X, Shou Q, Zheng M, et al. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. Vaccine. 2019;37(6):889–97. doi:10.1016/j.vaccine.2018.12.030.
  • Kjaer SK, Nygard M, Sundstrom K, Dillner J, Tryggvadottir L, Munk C, Berger S, Enerly E, Hortlund M, Ágústsson ÁI, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. E Clin Med. 2020;23:100401.
  • Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. Jama. 2002;287(16):2114–19. doi:10.1001/jama.287.16.2114.
  • Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–57. doi:10.1016/S0140-6736(09)60691-7.
  • Yoshikawa H, Ebihara K, Tanaka Y, Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci. 2013;104(4):465–72. doi:10.1111/cas.12106.
  • Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–27. doi:10.1093/cid/ciw354.
  • Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, Bennett NM, Johnson Jones ML, Whitney E, Pemmaraju M, Brackney M, et al. Trends in high-grade cervical lesions and cervical cancer screening in 5 states, 2008–2015. Clin Infect Dis. 2019;68(8):1282–91. doi:10.1093/cid/ciy707.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.